PET/MRI (AXUMIN) STUDY OF MEN WITH HIGHLY SUSPICIOUS MRI LESIONS THAT SHOWED NO CLINICALLY SIGNIFICANT PROSTATE CANCER FOLLOWING MRI FUSION TARGETED BIOPSY

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Prostate Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male
  • Other Inclusion Criteria:
    1. The participant has undergone MRFTB of an MRI lesion at the Department of Urology or at NYU Langone Health within past 12 months and has signed informed consent to participate in the NYU Urology prostate biopsy database. 2. The most recent MRFTB of a PIRADS 4 or 5 lesion did not show clinically significant prostate cancer.

You may not be eligible for this study if the following are true:

  • 1. The urologist who performed the initial MRFTB does not feel a repeat MRI is indicated. 2. Any contraindication to prostate biopsy including untreated urinary tract infection 3. Prior allergic reaction to axumin 4. Patient refuses MRI


If you are registered as a volunteer, please login to the dashboard to send referrals.